Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes

Title: Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes

Volume: 1 Issue: 2

Author(s): Bidyut Roy

Affiliation:

Keywords: anti-tuberculosis drugs, hepatotoxicity, polymorphism, gstm1, nat2, cyp genes

Abstract: Anti-tuberculosis drug induced (ATD) hepatotoxicity is uncommon and unpredictable. It might be related to drug itself or reactive metabolites derived from the drugs in vivo. Several demographic characteristics, such as race, age, sex, body mass index, alcohol intake, have been reported to be susceptibility risk factors for hepatotoxicity related to ATDs. There is now evidence that genetic variations or polymorphisms in biotransformation or detoxification systems controlled by NAT2, GSTM1 etc., might modulate the toxic effects of some drugs. Since prevalences of polymorphisms are different in different ethnic populations, the incidences of ATD hepatotoxicity vary in populations. Thus, knowledge of prevalences of polymorphisms in these genes in a population, prior to medication, may be useful in evaluating the risk and controlling ATD hepatotoxicity.

Cite this article as:

Roy Bidyut, Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes, Current Pharmacogenomics 2003; 1 (2) . https://dx.doi.org/10.2174/1570160033476340